Target intelligence / Profile preview

Double PHD fingers 3 (DPF3)

Target
DPF3
Molecular classification
Chromatin remodeling factor, Epigenetic regulator, Histone modification "reader", Transcription regulator
01

Overview

Double PHD fingers 3 (DPF3), also known as zinc finger protein DPF3 or BAF45C, is a **transcription regulator and epigenetic reader** that binds acetylated and methylated histone tails through its two plant homeodomain (PHD) zinc finger motifs[1][2][3][4][5]. DPF3 is a key component of the BAF (BRG1/BRM-associated factor) chromatin remodeling complex, which regulates gene accessibility and transcription by altering DNA-nucleosome topology. DPF3 serves as a tissue-specific anchor between histone modifications and chromatin remodeling, and it is especially important in **heart and skeletal muscle development**, as well as in the regulation of muscle-specific gene expression[2][3]. In pathology, DPF3 is associated with cancers (notably breast cancer and chronic lymphocytic leukemia) and congenital heart diseases. Mechanistically, DPF3 modulates pathways including the JAK2/STAT3 signaling axis, and its dysregulation promotes increased cell proliferation and motility in cancer cells[1][6]. No drugs directly targeting DPF3 are currently approved or widely reported. Altered expression of DPF3 can serve as a **biomarker** for cancer risk and progression[1][6].

Other names
Zinc finger protein DPF3BAF45CCERD4Cerd4FLJ14079SMARCG3BRG1-associated factor 45CD4Zinc and double PHD fingers, family 3
02

Mechanism of action

Epigenetic modulation by binding acetylated and methylated lysine residues on histones, affecting gene transcription; Scaffold/recruitment for chromatin remodeling complexes (BAF/SWI-SNF)

03

Biological functions

Chromatin remodelingRegulation of transcriptionHistone modification recognition (binds acetylated and methylated lysine residues on histone H3 and H4)Cell proliferationHeart and skeletal muscle development
04

Disease associations

Cancer (notably breast cancer, chronic lymphocytic leukemia)Cardiovascular disease (e.g., congenital heart defects such as atrial septal defect 9)Melanomatosis
05

Safety considerations

Potential for widespread gene expression changes due to interference with chromatin remodelingEssential role in heart development raises concerns for cardiotoxicity if inhibited systemically
06

Biomarkers

DPF3 expression levels (associated with cancer prognosis, e.g., breast cancer risk and severity)[1][6]

Beyond the preview

Go deeper on Double PHD fingers 3 (DPF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Double PHD fingers 3 (DPF3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call